Table 1.

Patient demographic and baseline characteristics

Characteristic (n = 17)N (%)
Age, y
 ≥654 (23.5%)
 <6513 (76.5%)
 Median (range)58 (22–74)
Sex
 Male10 (58.8%)
 Female7 (41.2%)
ECOG Performance Status
 ≤117 (100%)
Diagnosis
De novo AML13 (76.5%)
 Secondarya3 (17.6%)
 MDS, RAEB-21 (5.9%)
Relapsed versus primary refractory
 Primary refractory17 (100%)
Risk category (ELN 2017)
 Favorable1 (5.9%)
 Intermediate4 (23.5%)
 Poor12 (70.6%)
Cytogenetics
 Complex karyotype7 (41.2%)
 5q deletion4 (23.5%)
 Monosomal karyotype1 (5.9%)
 Normal karyotype5 (29.4%)
Mutations
FLT3-ITD1 (5.9%)
FLT3-TKD1 (5.9%)
IDH1 or 23 (17.6%)
NPM11 (5.9%)
GATA21 (5.9%)
MECOM1 (5.9%)
TP531 (5.9%)
RUNX12 (11.8%)
ASXL11 (5.9%)
Baseline white cell blood count (× 109/L)
 ≥302 (11.8%)
 ≥10 to <301 (5.9%)
 <1014 (82.3%)
 Median (range)7.04 (0.1–55.7)
Baseline bone marrow blast count (%)
 ≥506 (35.3%)
 ≥20 to <502 (11.8%)
 <209 (52.9%)
 Median (range)19 (4.5–95)
Prior therapies
 7 + 3b15 (88.2%)
 Othersc2 (11.8%)
  • NOTE: Date of censoring: June 30, 2020.

  • Abbreviations: ECOG, Eastern Cooperative Oncology Group; ELN, European LeukemiaNet; MDS, RAEB-2, myelodysplastic syndrome, refractory anemia with excess blasts type 2.

  • aIncludes AML with myelodysplasia-related changes (n = 1), therapy-related myeloid neoplasm (n = 1), and evolved from chronic myelomonocytic leukemia (n = 1).

  • bIncludes two patients who subsequently received 5 + 2.

  • cOne patient received ADE (cytarabine, daunorubicin, and etoposide) and the other azacitidine plus venetoclax and daunorubicin.